RxDoctor Payments Data

Andrea Buccilli, MD

Ophthalmology · Lockport, NYNPI 1770724635

Payments from drug & device makers

$3,456in general payments, 2019–2025

Across 192 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$637
  • Bausch & Lomb Americas Inc.$597
  • Alcon$554
  • Novartis$485
  • Aerie Pharmaceuticals, Inc.$308
  • Sun Pharmaceutical Industries Inc.$229
  • plus $646 from 10 others

What the payments were for

  • Food & beverage$3,456100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,456 in reported general payments places this provider in the 70th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$101,680
Medicare patients
368
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine141$122,432
RestasisCyclosporine88$99,352
LumiganBimatoprost165$83,402
XiidraLifitegrast60$63,294
RocklatanNetarsudil Mesylat/Latanoprost58$41,690
CequaCyclosporine15$18,240
Latanoprost649$14,639
Travoprost47$13,239
MieboPerfluorohexyloctane/Pf16$12,046
RhopressaNetarsudil Mesylate17$9,068
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$8,072
Alphagan PBrimonidine Tartrate20$8,018
Timolol Maleate60$7,618
VyzultaLatanoprostene Bunod11$6,966
SimbrinzaBrinzolamide/Brimonidine Tart14$4,866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$637$190,771273 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$597$82,30687 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$308$50,75875 claims
Sun Pharmaceutical Industries Inc.Cequa$229$18,24015 claims
AlconSimbrinza$554$4,86614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Lockport

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →